{
    "clinical_study": {
        "@rank": "82497", 
        "arm_group": [
            {
                "arm_group_label": "etifoxine (Anxiolytic)", 
                "arm_group_type": "Experimental", 
                "description": "etifoxine, 100 mg, a single oral intake"
            }, 
            {
                "arm_group_label": "lorazepam", 
                "arm_group_type": "Active Comparator", 
                "description": "lorazepam, 2 mg, a single oral intake"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "2 capsules of Placebo, a single oral intake"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the effects of etifoxine (an anxiolytic) compared\n      to lorazepam (a benzodiazepine anxiolytic) on vigilance and cognitive functions in the\n      elderly."
        }, 
        "brief_title": "Evaluation of the Effects of Etifoxine 100 mg and Lorazepam 2 mg on Vigilance and Cognitive Functions in the Elderly", 
        "condition": "Healthy Volunteers", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Man or woman aged from 65 to 75 years\n\n          -  Right-handed subject (Edinburgh Handedness inventory)\n\n          -  Subject having signed the consent form\n\n          -  Subject having agreed to be listed on the French National Healthy Volunteers database\n\n          -  Subject affiliated or beneficiary to French social insurance\n\n        Exclusion Criteria:\n\n          -  Subject presenting a neurological or psychiatric disease notably cognitive,\n             progressing\n\n          -  Anxious subject (Hamilton score > 7 and/or Spielberger score > 51 for a man or > 61\n             for a woman)\n\n          -  Left-handed subject (Edinburgh Handedness inventory)\n\n          -  Subject presenting a not corrected visual disease or a motor function disease that\n             could interfere with tests realization\n\n          -  Smoker\n\n          -  Subject taking one or more psychotropics or apparent products\n\n          -  Subject having taken, during the previous month, one or more drugs that could\n             interfere with study drugs metabolism\n\n          -  Subject drinking too much coffee or tea (> 4 cups per day) or alcohol (>\u00bd liter of\n             wine or equivalent per day)\n\n          -  Subject presenting contra-indication to one of the drugs used in the study\n\n          -  Subject with past history of intolerance to drugs used in the study\n\n          -  Subject not capable to use the CANTAB cognitive evaluation system\n\n          -  Subject which may not be able to participate to the whole study\n\n          -  Subject under tutelage or guardianship\n\n          -  Subject not able to well-understand French and so to understand cognitive tests\n\n          -  Subject not capable to swallow capsules\n\n          -  Subject participating to another study or in exclusion period (3 months after a\n             previous trial)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "75 Years", 
            "minimum_age": "65 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 22, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02147548", 
            "org_study_id": "ETILANCE - ETI 175"
        }, 
        "intervention": [
            {
                "arm_group_label": "etifoxine (Anxiolytic)", 
                "intervention_name": "etifoxine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "lorazepam", 
                "intervention_name": "lorazepam", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Lorazepam", 
                "Etifoxine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 22, 2014", 
        "location": {
            "contact": {
                "email": "dominique.deplanque@chru-lille.fr", 
                "last_name": "DEPLANQUE Dominique, MD, PhD", 
                "phone": "0033320445449"
            }, 
            "facility": {
                "address": {
                    "city": "Lille", 
                    "country": "France", 
                    "zip": "59037"
                }, 
                "name": "Centre d'Investigation Clinique, CIC 1403 INSERM/CHRU"
            }, 
            "investigator": {
                "last_name": "DEPLANQUE Dominique, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "3", 
        "official_title": "Evaluation of the Effects of Etifoxine 100 mg and Lorazepam 2 mg on Vigilance and Cognitive Functions in the Elderly. A Monocentric, Randomized, Cross-over, Double-blind Clinical Study Versus Placebo", 
        "overall_contact": {
            "last_name": "Pr DEPLANQUE Dominique, MD, PhD", 
            "phone": "0033320445449"
        }, 
        "overall_contact_backup": {
            "last_name": "DEPLANQUE Dominique, MD, PhD", 
            "phone": "0033320445449"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Reaction time (RTI) of Cambridge Neuropsychological Test Automated Batteries (CANTAB)", 
            "safety_issue": "No", 
            "time_frame": "2 hours after the study treatment intake"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02147548"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Biocodex", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Biocodex", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}